What is stock analysis? Well, there are some that think it has everything to do with the dividend. There are others that only look at charts. There are others that think that analyst estimate misses (notice how this is equivalent to companies' earnings beats) are a way to gauge the trajectory of a stock. And yet there are other groups that are lost in medieval times. We as investors need to move beyond these individual frameworks and start taking a holistic view. Let's take a look at what we mean as it relates to our analysis with DuPont (NYSE:DD).

At our independent investment research firm, we think a comprehensive analysis of a firm's discounted cash-flow valuation, relative valuation versus industry peers, as well as an assessment of technical and momentum indicators is the best way to identify the most attractive stocks at the best time to buy. This process culminates in what we call our Valuentum Buying Index, which ranks stocks on a scale from 1 to 10, with 10 being the best. Essentially, we're looking for firms that overlap investment methodologies, thereby revealing the greatest interest by investors (we like firms that fall in the center of the diagram below). More interest in the stock = more buying = higher stock price.

If a company is undervalued both on a DCF and on a relative valuation basis and is showing improvement in technical and momentum indicators, it scores high on our scale. DuPont posts a VBI score of 7 on our scale, reflecting our 'fairly valued' DCF assessment of the firm, its attractive relative valuation versus peers, and very bullish technicals. We compare DuPont to peers Airgas (NYSE:ARG), Dow Chemical (NYSE:DOW), and Praxair (NYSE:PX).

**Investment Considerations**

**Investment Highlights**

â˘ DuPont's scores fairly well on our business quality matrix. The firm has put up solid economic returns for shareholders during the past few years with relatively low volatility in its operating results. Return on invested capital (excluding goodwill) has averaged 15% during the past three years.

â˘ DuPont has a good combination of strong free cash flow generation and manageable financial leverage. We expect the firm's free cash flow margin to average about 10.6% in coming years. Total debt-to-EBITDA was 2.2 last year, while debt-to-book capitalization stood at 54%.

â˘ DuPont is targeting a long-term sales CAGR of 7% due to secular trends in food, energy and protection coupled with new products/applications. It expects a 12% long-term earnings CAGR due to higher margins on new products and ongoing productivity enhancements. If achieved, there is upside to our fair value estimate.

**Business Quality**

**Economic Profit Analysis**

The best measure of a firm's ability to create value for shareholders is expressed by comparing its return on invested capital (ROIC) with its weighted average cost of capital (OTC:WACC). The gap or difference between ROIC and WACC is called the firm's economic profit spread. DuPont's 3-year historical return on invested capital (without goodwill) is 15%, which is above the estimate of its cost of capital of 10.9%. As such, we assign the firm a ValueCreationâ˘ rating of GOOD. In the chart below, we show the probable path of ROIC in the years ahead based on the estimated volatility of key drivers behind the measure. The solid grey line reflects the most likely outcome, in our opinion, and represents the scenario that results in our fair value estimate.

**Cash Flow Analysis**

Firms that generate a free cash flow margin (free cash flow divided by total revenue) above 5% are usually considered cash cows. DuPont's free cash flow margin has averaged about 8.4% during the past 3 years. As such, we think the firm's cash flow generation is relatively STRONG. The free cash flow measure shown above is derived by taking cash flow from operations less capital expenditures and differs from enterprise free cash flow (FCFF), which we use in deriving our fair value estimate for the company. For more information on the differences between these two measures, please visit our website at Valuentum.com. At DuPont, cash flow from operations decreased about 3% from levels registered two years ago, while capital expenditures expanded about 19% over the same time period.

**Valuation Analysis**

Our discounted cash flow model indicates that DuPont's shares are worth between $43-$71 each. The margin of safety around our fair value estimate is driven by the firm's MEDIUM ValueRiskâ˘ rating, which is derived from the historical volatility of key valuation drivers. Ever wonder why we use such a large margin of safety? Click here. The estimated fair value of $57 per share represents a price-to-earnings (P/E) ratio of about 21.8 times last year's earnings and an implied EV/EBITDA multiple of about 11.6 times last year's EBITDA. Our model reflects a compound annual revenue growth rate of 5% during the next five years, a pace that is lower than the firm's 3-year historical compound annual growth rate of 8.9%. Our model reflects a 5-year projected average operating margin of 14.9%, which is above DuPont's trailing 3-year average. Beyond year 5, we assume free cash flow will grow at an annual rate of 3.6% for the next 15 years and 3% in perpetuity. For DuPont, we use a 10.9% weighted average cost of capital to discount future free cash flows.

**Margin of Safety Analysis**

Our discounted cash flow process values each firm on the basis of the present value of all future free cash flows. Although we estimate the firm's fair value at about $57 per share, every company has a range of probable fair values that's created by the uncertainty of key valuation drivers (like future revenue or earnings, for example). After all, if the future was known with certainty, we wouldn't see much volatility in the markets as stocks would trade precisely at their known fair values. Our ValueRiskâ˘ rating sets the margin of safety or the fair value range we assign to each stock. In the graph below, we show this probable range of fair values for DuPont. We think the firm is attractive below $43 per share (the green line), but quite expensive above $71 per share (the red line). The prices that fall along the yellow line, which includes our fair value estimate, represent a reasonable valuation for the firm, in our opinion.

**Future Path of Fair Value**

We estimate DuPont's fair value at this point in time to be about $57 per share. As time passes, however, companies generate cash flow and pay out cash to shareholders in the form of dividends. The chart below compares the firm's current share price with the path of DuPont's expected equity value per share over the next three years, assuming our long-term projections prove accurate. The range between the resulting downside fair value and upside fair value in Year 3 represents our best estimate of the value of the firm's shares three years hence. This range of potential outcomes is also subject to change over time, should our views on the firm's future cash flow potential change. The expected fair value of $73 per share in Year 3 represents our existing fair value per share of $57 increased at an annual rate of the firm's cost of equity less its dividend yield. The upside and downside ranges are derived in the same way, but from the upper and lower bounds of our fair value estimate range.

**Pro Forma Financial Statements**

**Disclosure: **I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.